Profile data is unavailable for this security.
About the company
Nanjing Vazyme Biotech Co Ltd is China-based company principally engaged in life sciences, in vitro diagnostics, and biopharmaceuticals. Its products and services cover basic research reagents, high-throughput sequencing reagents, diagnostic raw materials, laboratory consumables and instruments, pharmaceutical R&D reagents, vaccine evaluation reagents and raw materials, etc. The company's products are mainly used in scientific research, high-throughput sequencing, molecular diagnostics, in vitro diagnostics, pharmaceutical, vaccine research and development, animal husbandry, and animal quarantine. The Company mainly conducts its business in the domestic and overseas markets.
- Revenue in CNY (TTM)1.34bn
- Net income in CNY-29.64m
- Incorporated2012
- Employees2.87k
- LocationNanjing Vazyme Biotech Co Ltd1-6F, East Section, Building C1-2Hongfeng Science and Technology ParkKechuang Road, Economic and TechnologicaNANJING 210033ChinaCHN
- Phone+86 2 585771179
- Fax+86 2 585771171
- Websitehttps://www.vazyme.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Animal Husbandry Industry Co., Ltd | 6.28bn | 214.44m | 7.98bn | 4.30k | 37.19 | 1.39 | -- | 1.27 | 0.21 | 0.21 | 6.15 | 5.60 | 0.6863 | 5.30 | 4.19 | 1,461,064.00 | 2.32 | 5.25 | 3.37 | 7.48 | 15.59 | 22.15 | 3.38 | 7.31 | 1.62 | -- | 0.1625 | 31.16 | 11.30 | 7.79 | -82.41 | -22.24 | -0.0699 | -21.83 |
| Zhejiang Ausun Pharmaceutical Co Ltd | 751.12m | 184.84m | 8.20bn | 1.22k | 44.04 | 3.49 | -- | 10.91 | 0.2241 | 0.2241 | 0.8963 | 2.83 | 0.2472 | 0.9248 | 3.00 | 616,180.10 | 6.08 | 8.91 | 7.77 | 12.10 | 51.51 | 53.44 | 24.61 | 27.68 | 2.17 | -- | 0.1383 | 27.35 | -2.63 | 20.90 | -18.55 | 29.68 | 17.53 | 43.79 |
| Guangxi Wuzhou Zhongheng Group Co Ltd | 2.29bn | -363.56m | 8.22bn | 2.97k | -- | 1.42 | -- | 3.58 | -0.1112 | -0.1112 | 0.7189 | 1.82 | 0.204 | 2.09 | 3.30 | 771,487.60 | -4.90 | -0.1745 | -7.79 | -0.2739 | 34.13 | 64.36 | -24.05 | -0.6631 | 2.01 | -5.26 | 0.2563 | 69.54 | -26.67 | -9.85 | -547.14 | -- | 4.41 | -- |
| Changchun BCHT Biotechnology Co | 677.51m | -170.53m | 8.31bn | 1.27k | -- | 2.10 | -- | 12.27 | -0.4124 | -0.4124 | 1.64 | 9.57 | 0.1288 | 0.7183 | 0.4756 | 531,801.10 | -3.24 | 8.14 | -4.12 | 10.19 | 77.22 | 85.58 | -25.17 | 23.29 | 1.20 | -8.89 | 0.0696 | 14.91 | -32.64 | 4.73 | -53.67 | 0.9824 | 33.40 | -- |
| Sichuan Huiyu Pharmaceutical Co Ltd | 984.29m | 47.23m | 8.31bn | 1.38k | 175.96 | 2.23 | -- | 8.44 | 0.1115 | 0.1115 | 2.32 | 8.81 | 0.1983 | 0.9536 | 14.36 | 712,220.30 | 0.8073 | 8.62 | 1.04 | 10.46 | 80.54 | 88.41 | 4.07 | 22.26 | 2.63 | -- | 0.1185 | 24.48 | 18.05 | 9.13 | 132.78 | 12.96 | 3.11 | -- |
| Nanjing Vazyme Biotech Co Ltd | 1.34bn | -29.64m | 8.35bn | 2.87k | -- | 2.17 | -- | 6.21 | -0.0817 | -0.0817 | 3.98 | 9.66 | 0.2715 | 1.10 | 2.75 | 468,919.20 | -0.6649 | 9.69 | -0.8034 | 11.88 | 68.89 | 69.81 | -2.45 | 20.70 | 3.34 | -- | 0.1832 | 35.88 | 7.15 | 38.71 | 74.50 | -- | 30.38 | -- |
| Jiangsu Kanion Pharmaceutical Co., Ltd. | 3.13bn | 234.36m | 8.36bn | 6.13k | 35.71 | 1.77 | -- | 2.67 | 0.4136 | 0.4136 | 5.50 | 8.33 | 0.459 | 2.03 | 5.49 | 510,570.90 | 3.29 | 5.72 | 4.42 | 8.14 | 67.90 | 72.85 | 7.18 | 9.42 | 1.73 | 47.38 | 0.0006 | 18.39 | -19.86 | -3.11 | -15.58 | -5.02 | -0.5518 | -- |
Data as of Feb 11 2026. Currency figures normalised to Nanjing Vazyme Biotech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
3.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Harvest Fund Management Co., Ltd.as of 30 Jun 2025 | 3.36m | 0.85% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 1.66m | 0.42% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 1.58m | 0.40% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2025 | 1.28m | 0.32% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 1.14m | 0.29% |
| Hongde Fund Management Co., Ltd.as of 30 Jun 2025 | 1.07m | 0.27% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 951.77k | 0.24% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 709.01k | 0.18% |
| Huisheng Fund Management Co., Ltd.as of 30 Jun 2025 | 605.04k | 0.15% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2025 | 562.96k | 0.14% |
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
